India has received zero-tariff treatment for certain specialty pharmaceutical products and related ingredients under the United States’ new pharmaceutical tariff framework.
The U.S. Commerce Department has included India among 20 eligible jurisdictions for the special treatment. The measure takes effect against the backdrop of a broader U.S. policy imposing a 100% ad valorem tariff on specified patented pharmaceutical products and associated ingredients.
Editorial Insight
Key Highlights
Important points readers should notice.
India: Included among 20 jurisdictions eligible for zero-tariff treatment on specified specialty pharmaceutical products.
Products: Coverage includes selected rare-disease, fertility, cell and gene therapy and other specialty medicines.
Tariff: A 100% U.S. tariff applies to specified patented pharmaceutical products under the broader Section 232 framework.
Generic Drugs: Generic pharmaceutical products and associated ingredients remain outside this particular tariff regime.
Effective Date: The broader tariff treatment expands to additional covered companies from September 29, 2026.
The exemption is not a blanket waiver for all Indian pharmaceutical exports. It applies to defined categories of specialty medicines and their associated ingredients.
Eligible categories include medicines whose approved indications are designated for rare diseases, nuclear medicines, plasma-derived therapies, fertility treatments, cell therapies, gene therapies and antibody-drug conjugates. Certain medical countermeasures and eligible animal-health pharmaceutical products are also covered under the framework.
The U.S. framework also provides zero-tariff treatment for qualifying pharmaceutical products from jurisdictions that meet specified trade and security conditions with Washington, or where products are determined to address an urgent U.S. health need.
Editorial Analysis
Why This Matters
The decision creates an important distinction for Indian pharmaceutical exporters operating in the U.S. market. Companies supplying qualifying specialty medicines may avoid the additional tariff burden for products covered by the exemption. At the same time, exporters need to determine whether individual products meet the specific classification and origin requirements rather than treating the announcement as a universal exemption for Indian pharmaceuticals. For the Indian pharmaceutical industry, the policy could therefore have different effects across specialty medicines, patented products and generic drugs.
For Indian pharmaceutical manufacturers, the distinction between specialty medicines and other pharmaceutical products is important. The latest decision does not mean every patented or branded medicine exported from India will enter the U.S. market without the new tariff.
At the same time, generic pharmaceutical products and their associated ingredients remain outside the Section 232 pharmaceutical tariffs, according to the U.S. Commerce Department framework.
The broader tariff policy was introduced as part of Washington’s effort to encourage greater pharmaceutical manufacturing in the United States. Under the April 2026 proclamation, the 100% tariff applies to specified patented pharmaceutical products and associated ingredients, with the tariff treatment becoming effective for additional covered companies from September 29, 2026.
